### **Overview** Jubilant Ingrevia Ltd is a globally integrated life sciences and specialty chemicals company formed in February 2021 through the demerger of the Life Science Ingredients (LSI) business from Jubilant Life Sciences. Headquartered in India, the company operates across three core verticals: **Specialty Chemicals**, **Nutrition & Health Solutions**, and **Chemical Intermediates**. With over 45 years of heritage (originating as VAM Organics), it has evolved from a chemical manufacturer into a technology-enabled CDMO (Contract Development and Manufacturing Organization) and specialty solutions provider serving pharmaceuticals, agrochemicals, nutrition, personal care, electronics, and industrial sectors. --- ### **Strategic Vision: Pinnacle 345 to 2030** Jubilant Ingrevia launched its **"Pinnacle" strategy** with ambitious long-term goals: - **Triple revenue** and **quadruple EBITDA** over five years (by FY27). - Expand CDMO business **5x by FY27** and **~10x by FY30**. - Shift portfolio to ensure **75–80% of revenue** comes from **Specialty & Nutrition segments** by FY30. - Transition from a **product-centric** to a **service-led CDMO model**, creating long-term, high-margin partnerships. This transformation is driven by global supply chain shifts ("China+1"), rising demand for high-tech and high-margin chemicals, digital innovation, and sustainability. --- ### **Core Business Segments** #### 1. **Specialty Chemicals (~44% of FY25 revenue, 72% of EBITDA)** Jubilant Ingrevia is a **global leader** in **pyridine and picolines**, and the **world’s largest non-Chinese producer** in this space. It holds **#1 positions in 36 pyridine derivatives**, growing at **>15% annually**, and ranks **top-2 globally in Vitamin B3 (Niacinamide)** and **Acetic Anhydride**. **Sub-Segments:** - **Pyridine & Picolines:** Used in pharmaceuticals, agrochemicals, electronics, and oilfield applications. - **Fine Chemicals:** Amino pyridines, halo pyridines, carboxylic acids—used in drugs like Esomeprazole, Linagliptin, Dabigatran, and Palbociclib. - **Diketene Derivatives:** Strategic growth platform; operates a **7,000 TPA diketene facility**. Achieved **70% utilization in 2 years**, growing >50% YoY. Plans to launch 10+ derivatives and target top-3 global ranking. - **Custom Development & Manufacturing (CDMO):** Focus on pharma, agro, and **semiconductor chemicals**. - **Microbial Control Solutions (MCS):** Anti-dandruff (ZPTO), antimicrobials, biocides for paints, coatings, and personal care. **Recent FY25 Highlights (Aug 2025):** - Revenue: ₹18,180 Cr (+15% YoY) - EBITDA: ₹4,220 Cr (+70% YoY) - 15 pharma CDMO pipeline molecules in advanced stages. --- #### 2. **Nutrition & Health Solutions (~38% of FY25 revenue)** A dual focus on **Human Nutrition** and **Animal Nutrition & Health**. The company aims to scale this segment with 15–20% CAGR and EBITDA margins of 16–18%. - **Human Nutrition:** - Launched **food- and cosmetic-grade Choline Chloride (CC)** and **Choline Bitartrate (CBT)**. - Commissioned a **new 5,000 TPA Niacinamide plant** for food/cosmetics use—fully integrated, green supply chain. - Developing **nutraceutical premixes**, choline salts, and **flush-free niacin (Inositol Hexa nicotinate)**. - **Animal Nutrition:** - Global **top-2 in Vitamin B3 (Niacinamide)** for animal feed. - #1 domestic supplier of **Vitamin B4 (Choline Chloride)**. - Premium brands: **Phytoshield** (herbal, non-antibiotic growth promoter) and **Anichol**. **FY25 Revenue:** ₹750 Cr **Growth Driver:** Expansion in high-margin human nutrition applications and US/EU markets. --- #### 3. **Chemical Intermediates (18% of revenue)** Serves as a **cash-generating foundation** with full integration into acetyls and ketene chemistry. Key products: - **Acetic Anhydride:** Among top-2 global producers; new **210,000 TPA plant** in Bharuch. - **Ethyl Acetate:** Eco-friendly solvent (carbon footprint 60% lower than petro route). - **Bio-based Acetaldehyde:** World’s largest producer, low-carbon, renewable. - **Green Acetic Acid:** 99%+ biogenic content; FSSAI, ISO 22000, Kosher, Halal certified. --- ### **CDMO: Future Growth Engine** Jubilant Ingrevia is aggressively scaling its CDMO business, which is expected to become a **key revenue and margin driver**. **Segments:** - **Pharma CDMO:** 15 active molecules, including **Phase 3 and launch-stage products**. - **Agro CDMO:** Secured **$300M+ 5-year global contract**; dedicated plant completion expected **Oct–Nov 2025**, with revenue from Q4 FY26. - **Semiconductor CDMO:** Entry into **high-growth sector** with **8–10 molecules at kilogram scale**, samples supplied to multiple clients. First **commercial order expected FY26**. **Key Features:** - **8–10 Late-Phase & Launch-Stage Partnerships** with global innovators. - **Rigorous Pilot-to-Plant Workflow** reduces time to market. - **70% firm purchase order visibility** for 5x scale-up by FY27. **Capacity:** - **GMP facility in Bharuch:** Validation batches progressing to **Drug Master File (DMF)** filings. - New **multipurpose plant under construction at Gajraula**. --- ### **Innovation & R&D Leadership** Jubilant Ingrevia is India’s **first chemical-plant Lighthouse Factory** recognized by the **World Economic Forum**, due to its digital and green innovations. **R&D Infrastructure (as of Oct 2025):** - **3 Centers:** Greater Noida (flagship), Gajraula, Bharuch - **~150 Scientists**, including ~30 PhDs - **100+ patents** and multiple DSIR-recognized facilities **Innovation Focus:** - **AI & GenAI:** Used in retrosynthesis, impurity prediction, and experimental design—accelerates R&D timelines and reduces costs. - **Flow Chemistry & Continuous Manufacturing:** Improves safety, scalability, and sustainability. - **Green Chemistry:** Elimination of hazardous reagents (e.g., via **continuous ozonolysis**), effluent treatment, and renewable feedstocks. Over **50+ products** currently in development across specialties, nutrition, and CDMO. --- ### **Manufacturing & Global Presence** - **5 Integrated Manufacturing Complexes** in Gajraula (UP), Bharuch & Savli (Gujarat), Nira & Ambernath (Maharashtra) - **50+ plants**, with **multi-purpose facilities (MPFs)** enabling flexible and rapid scale-up. - **SEZ Facility in Bharuch:** Houses the **world’s largest Vitamin B3 plant** and key cGMP units. - **Storage Hubs:** Europe and South Korea for supply chain continuity. - **Digital Monitoring & Automation:** IoT, cloud computing, and AI/ML in operations; **real-time performance tracking**. --- ### **Global Expansion & Customer Base** - **~1,500 customers in 63 countries**, including **15 of top 20 global pharma** and **7 of top 10 agrochemical firms**. - **46% Export Revenue** (up from 41% in FY24), with strong growth in **North America (+52% YoY)** and **Europe**. - **Global Offices:** US, Europe, China, Japan—supported by **CXO-level engagement** and customer roadshows. - **$24B addressable market**, capitalizing on “China+1” sourcing shifts. --- ### **Key Growth Projects (On Track for FY26)** | Project | Location | Timeline | Impact | |--------|---------|--------|--------| | **Agro-Innovator Project (₹300M+)** | Bharuch | Q4 FY26 commissioning | Revenue commencement Q4 FY26 | | **New Boiler Commissioning** | Bharuch | Q3 FY26 | Enhanced efficiency | | **Multipurpose Plant** | Gajraula | Under construction | Flexibility for CDMO growth | | **Semiconductor R&D Facility** | Greater Noida | Under planning | Entry into high-tech innovation | | **New CDMO Launches** | Pan-India | FY26 | 18 new products targeted | --- ### **Competitive Advantages** - **Vertically Integrated Value Chain** from raw materials to finished products. - **Deep Chemistry Expertise:** 35+ complex chemistry platforms and 13-step multi-synthesis capability. - **Cost Leadership:** Lowest-cost pyridine and B3 producer due to captive feedstocks and green processes. - **Regulatory Compliance:** WHO GMP, FSSAI, REACH, USFDA inspections (Bharuch Unit-1). - **Sustainability Focus:** Bio-based, low-carbon, and renewable processes with Responsible Care certification.